Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased due to a rise in the number of atrial fibrillation ablation cases, higher sales volumes of core and new products, an increase in the number of adopting facilities, marketing initiatives, and the development of new sales channels. Meanwhile, personnel expenses, research and development expenses, and selling-related expenses increased. For the next fiscal year, the Company expects lower selling prices following revisions to official prices, higher raw material and labor costs, higher service prices, strategic wage increases, research and development investment, and expenses related to the relocation of the head office.
No applicable matters (There are no applicable matters.)
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥59,187 million (YoY +4.6%) |
| Operating profit | ¥12,606 million (YoY +2.3%) |
| Ordinary income | ¥12,588 million (YoY +2.1%) |
| Profit attributable to owners of the parent | ¥9,350 million (YoY +0.4%) |
| Net income per share | ¥133.30 |
| Operating Margin | 21.3% |
| Equity ratio | End of the current fiscal period 82.1% / End of previous period 79.8% |
| Total assets | ¥80,211 million |
| Net assets | ¥65,897 million |
| Cash flows from operating activities | ¥8,172 million |
| Cash flows from investing activities | ¥-2,048 million |
| Cash flows from financing activities | ¥-4,581 million |
| Cash and cash equivalents at end of period | ¥12,494 million |
| Full-year earnings forecast | Net Sales ¥63,200 million (YoY +6.8%) / Operating profit ¥10,700 million (YoY -15.1%) / Ordinary income ¥10,800 million (YoY -14.2%) / Net income ¥8,000 million (YoY -14.4%) |
| Annual Dividend Forecast | ¥53 → ¥56（+5.7%） |
| Payout ratio | 40.5% (actual for the fiscal year ended March 2026), 49.1% (forecast for the fiscal year ending March 2027) |
| Depreciation and amortization | ¥1,656 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥0 million, Item Gain on sale of investment securities / Amount ¥18 million / Extraordinary loss Item Loss on sale of fixed assets / Amount ¥16 million, Item Loss on Disposal of Fixed Assets / Amount ¥85 million, Item Loss on sale of investment securities / Amount ¥18 million, Item Head Office Relocation Costs / Amount ¥108 million |
| Disclosure regarding the going concern assumption | No applicable matters (There are no applicable matters.) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts) |
| Issued Shares at Period-End | 71,300,000 Shares |
| Treasury Shares at Period-End | 1,145,522 Shares |
| Factors Behind Changes in Business Performance | Net sales increased due to a rise in the number of atrial fibrillation ablation cases, higher sales volumes of core and new products, an increase in the number of adopting facilities, marketing initiatives, and the development of new sales channels. Meanwhile, personnel expenses, research and development expenses, and selling-related expenses increased. For the next fiscal year, the Company expects lower selling prices following revisions to official prices, higher raw material and labor costs, higher service prices, strategic wage increases, research and development investment, and expenses related to the relocation of the head office. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, higher case volumes and expanded sales of core and new products secured revenue growth. For the next fiscal year, operating profit is expected to decline due to lower selling prices following revisions to official prices, rising raw material and labor costs, higher IT service prices and wage increases, research and development investment, and expenses related to the relocation of the head office.